Moderna, Rovi expand collaboration with 10-year deal to make MRNA medicines
Maddie Meyer/Getty Images News


Moderna (NASDAQ:MRNA) and Laboratorios FarmacÃ©uticos Rovi expanded their partnership with a new 10 year agreement to manufacture MRNA medicines.
The collaboration will increase capacities for the compounding, aseptic filling, inspection, labeling, and packaging of ROVI's facilities, in Madrid, San SebastiÃ¡n de los Reyes and AlcalÃ¡ de Henares.

The new agreement, includes a series of investments expected to allow the manufacturing capacity to increase across ROVI's facilities in Madrid.
In addition to producing Moderna's COVID-19 vaccine, ROVI's platform could also be used to service future Moderna mRNA vaccine candidates.
The two companies are expected to finalize details of the agreement in the first quarter of 2022.
MRNA -1.11% pre-market to $149.45